ST91 [2-(2,6-diethylphenylamino)-2-imidazoline hydrochloride]-mediated spinal antinociception and synergy with opioids persists in the absence of functional α-2A- or α-2C-adrenergic receptors

Laura S. Stone, Kelley F Kitto, James C. Eisenach, Carolyn A Fairbanks, George L Wilcox

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Agonists acting at α2-adrenergic receptors (α2ARs) produce antinociception and synergize with opioids. The α2ARs are divided into three subtypes, α2AAR, α2BAR, and α2CAR. Most α2AR agonists require α2AAR activation to produce antinociception and opioid synergy. The same subtype also mediates the side effect of sedation, which limits the clinical utility of these compounds. Identification of a non-α2AAR-mediated antinociceptive agent would enhance the therapeutic utility of α2AR agonists in pain management. Previous studies have suggested that the α2AR agonist ST91 [2-(2,6-diethylphenylamino)-2-imidazoline hydrochloride] has a nonsedating, non-α2AAR mechanism of action. We examined the pharmacology of spinal ST91 and its interaction with the δ-opioid agonist deltorphin II (Tyr-D-Ala-Phe-Glu-Val-Val-Gly amide) in mice lacking either functional α2AARs or α2CARs. All drugs were administered by direct lumbar puncture, and drug interactions were evaluated using isobolographic analysis. In contrast to the majority of α2AR agonists, ST91 potency was only moderately reduced (3-fold) in the absence of the α2AAR. Studies with the α2AR subtype-preferring antagonists BRL-44408 (2-[2H-(1-methyl-1,3-dihydroisoindole) methyl]-4,5-dihydroimidazole maleate) and prazosin [[4-(4-amino-6,7-dimethoxy- quinazolin-2-yl) piperazin-1-yl]-(2-furyl)methanone] and the pan-α2AR antagonist SKF-86466 (6-chloro-2,3,4,5-tetrahydro-3- methyl-1-H-3-benzazepine) suggest a shift from α2AAR to the other α2AR subtype(s) in the absence of α2AAR. Antinociceptive synergy with deltorphin II was preserved in the absence of either α2AAR or α2CAR. In conclusion, ST91 activates both α2AAR and non-α2AAR subtypes to produce spinal antinociception and opioid synergy. This study confirms that the spinal pharmacology of ST91 differs from that of other α2AR agonists and extends those data to include spinal synergy with opioid agonists. The unique profile of ST91 may be advantageous in pain management.

Original languageEnglish (US)
Pages (from-to)899-906
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume323
Issue number3
DOIs
StatePublished - Dec 2007

Fingerprint

Dive into the research topics of 'ST91 [2-(2,6-diethylphenylamino)-2-imidazoline hydrochloride]-mediated spinal antinociception and synergy with opioids persists in the absence of functional α-2A- or α-2C-adrenergic receptors'. Together they form a unique fingerprint.

Cite this